首页> 外国专利> oral composition containing verabreichbare parecoxib

oral composition containing verabreichbare parecoxib

机译:含有韦拉布瑞帕瑞昔布的口服组合物

摘要

A pharmaceutical composition that is substantially free of water comprises at least one orally deliverable dosage unit comprising a therapeutically effective amount of a sulfonamide prodrug and, where the prodrug is readily degradable ex vivo, has means to inhibit such degradation prior to oral administration. Illustratively the prodrug is parecoxib or a water-soluble salt thereof, and the composition has means to inhibit conversion of the parecoxib to valdecoxib. A method of treating or preventing a COX-2 mediated disorder in a subject comprises (a) dissolving at least one dosage unit of such a composition in a pharmaceutically acceptable aqueous vehicle to form a solution, and (b) orally administering the solution to the subject before substantial precipitation of insoluble matter occurs in the solution.
机译:基本上不含水的药物组合物包含至少一个包含治疗有效量的磺酰胺前药的口服可递送剂量单位,并且在前药易于离体降解的情况下,该药物组合物具有在口服给药之前抑制这种降解的手段。说明性地,前药是帕瑞昔布或其水溶性盐,并且该组合物具有抑制帕瑞昔布向伐地昔布转化的手段。一种在受试者中治疗或预防COX-2介导的疾病的方法,其包括(a)将这种组合物的至少一个剂量单位溶解在药学上可接受的水溶媒中以形成溶液,以及(b)将该溶液口服给予该患者。受试者在溶液中出现大量不溶物沉淀之前。

著录项

  • 公开/公告号DE60224558D1

    专利类型

  • 公开/公告日2008-02-21

    原文格式PDF

  • 申请/专利权人 PHARMACIA CORP.;

    申请/专利号DE2002624558T

  • 发明设计人 KARIM AZIZ;NEMA SANDEEP;EWING GARY D.;

    申请日2002-11-12

  • 分类号A61K31/42;A61K47/48;A61K9/08;A61K9/14;A61K9/19;A61K9/20;A61K31/365;A61K31/415;A61K47/10;A61K47/20;A61K47/22;A61K47/26;A61K47/46;A61P29;A61P43;

  • 国家 DE

  • 入库时间 2022-08-21 19:47:49

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号